GLPwatch
Answers to Clinical Questions in the Primary Care Management of People with Obesity: Pharmacologic Management.
J Fam Pract · 2016
Last updated 2026-05-28Five medications—liraglutide, lorcaserin, naltrexone/bupropion extended-release, phentermine/topiramate extended-release, and orlistat—are now approved for long-term weight loss in adults with overweight (BMI of 27 or higher with at least one weight-related health issue) or obesity (BMI of 30 or higher). These drugs offer new options for managing weight in primary care settings.
AI summary of the abstract below.
| Journal | J Fam Pract, 2016 |
|---|---|
| Citations | 2 |
| Relative citation ratio | 0.07 |
| NIH percentile | 6 |
| Molecules | — |
| Conditions studied | Obesity |
Abstract
The recent approval of liraglutide, lorcaserin, naltrexone/bupropion extended-release, and phentermine/topiramate extended-release, brings the number of medications for long-term weight loss to 5 (including orlistat). Indicated for the treatment of patients with overweight (body mass index [BMI] ≥27 kg/m2 with ≥1 weight-related comorbidity) or obesity (BMI ≥30 kg/m2), these medications provide new opportunities to address this burgeoning health problem.
Verbatim abstract via PubMed 27565106 ↗